251 related articles for article (PubMed ID: 21918760)
21. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
23. Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions.
Mügge C; Liu R; Görls H; Gabbiani C; Michelucci E; Rüdiger N; Clement JH; Messori L; Weigand W
Dalton Trans; 2014 Feb; 43(8):3072-86. PubMed ID: 24169734
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(II) oxadiazoline complexes with potential cytotoxic properties.
Wagner G; Marchant A; Sayer J
Dalton Trans; 2010 Sep; 39(33):7747-59. PubMed ID: 20657943
[TBL] [Abstract][Full Text] [Related]
25. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
26. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand.
Marqués-Gallego P; Contaldi S; den Dulk H; Monari M; Brouwer J; Jaehde U; Kalayda GV; Reedijk J
J Inorg Biochem; 2009 Dec; 103(12):1602-8. PubMed ID: 19783310
[TBL] [Abstract][Full Text] [Related]
27. Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-acetate.
Bierbach U; Sabat M; Farrell N
Inorg Chem; 2000 May; 39(9):1882-90. PubMed ID: 11428108
[TBL] [Abstract][Full Text] [Related]
28. Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.
Cubo L; Groessl M; Dyson PJ; Quiroga AG; Navarro-Ranninger C; Casini A
ChemMedChem; 2010 Aug; 5(8):1335-43. PubMed ID: 20564276
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
30. The role of bridging ligands in determining DNA-binding ability and cross-linking patterns of dinuclear platinum(II) antitumour complexes.
Zhu J; Lin M; Fan D; Wu Z; Chen Y; Zhang J; Lu Y; Guo Z
Dalton Trans; 2009 Dec; (48):10889-95. PubMed ID: 20023919
[TBL] [Abstract][Full Text] [Related]
31. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
32. New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.
Ramos-Lima FJ; Quiroga AG; García-Serrelde B; Blanco F; Carnero A; Navarro-Ranninger C
J Med Chem; 2007 May; 50(9):2194-9. PubMed ID: 17407274
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, crystal structure, DNA-binding and cytotoxicity in vitro of novel cis-Pt(II) and trans-Pd(II) pyridine carboxamide complexes.
Shi CY; Gao EJ; Ma S; Wang ML; Liu QT
Bioorg Med Chem Lett; 2010 Dec; 20(24):7250-4. PubMed ID: 21071219
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
35. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
36. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
Marqués-Gallego P; Kalayda GV; Jaehde U; Dulk Hd; Brouwer J; Reedijk J
J Inorg Biochem; 2009 May; 103(5):791-6. PubMed ID: 19303143
[TBL] [Abstract][Full Text] [Related]
37. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
Kapp T; Dullin A; Gust R
J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
[TBL] [Abstract][Full Text] [Related]
38. In vitro biological evaluation of platinum(II) complexes with 1-(methoxy substituted benzyl) azetidine-3,3-dicarboxylato ligands.
Yin R; Gou S; Sun Y; Liu X
Bioorg Med Chem; 2012 Feb; 20(4):1461-7. PubMed ID: 22264764
[TBL] [Abstract][Full Text] [Related]
39. Monofunctional platinum(II) complexes with potent tumor cell growth inhibitory activity: the effect of a hydrogen-bond donor/acceptor N-heterocyclic ligand.
Margiotta N; Savino S; Gandin V; Marzano C; Natile G
ChemMedChem; 2014 Jun; 9(6):1161-8. PubMed ID: 24799414
[TBL] [Abstract][Full Text] [Related]
40. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
